Living With Parkinson’s Disease
as depression or anxiety. It is also clear that a change in mind-set is needed, in which we move away from a reliance on the UPDRS motor score to assess PD and the effect of treatments and towards a more holistic approach that considers the assessment of non-motor symptoms as well as motor symptoms. Other factors not covered by the existing scales (such as communication) may also be important to the patient’s QoL and our approach to measuring such factors will continue to evolve. Dopaminergic treatment helps reduce non-motor and motor symptoms, thus improving QoL, and the newer CDS
1. Grosset D, Taurah L, Burn DJ, et al., A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis, J Neurol Neurosurg Psychiatry, 2007;78:465–9.
2. Grosset D, Antonini A, Canesi M, et al., Adherence to antiparkinson medication in a multicenter European study, Mov Disord, 2009;24:826–32.
3. Onofrj M, Thomas A, Vingerhoets F, et al., Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study, J Neural Transm, 2004;111:1053–63.
4. Martinez-Martin P, Schapira AH, Stocchi F, et al., Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients, Mov Disord, 2007;22:1623–9.
5. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al., The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease, Mov Disord, 2011;26:399–406.
6. Adler CH, Nonmotor complications in Parkinson's disease, Mov Disord, 2005;20(Suppl. 11):S23–9.
7. Chaudhuri KR, Healy DG, Schapira AH, Non-motor symptoms of Parkinson's disease: diagnosis and management, Lancet Neurol, 2006;5:235–45.
8. Braak H, Del Tredici K, Rub U, et al., Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 2003;24:197–211.
9. Poewe W, The natural history of Parkinson's disease,
treatments could play a role in managing these symptoms. Indeed, this may be an important benefit of CDS treatments, to complement their effects on motor symptoms and potential benefits on adherence. However, more good quality clinical trial data are needed before this hypothesis can be proven and, thus, before recommendations can be made for early CDS treatment to improve QoL. Ongoing work will ensure a better understanding of the potential role of CDS treatments for managing non-motor symptoms and improving QoL. The aim is that the everyday lives of patients with PD will be greatly improved. n
J Neurol, 2006;253(Suppl. 7):VII2–6.
10. Gulati A, Forbes A, Stegie F, et al., A clinical observational study of the pattern and occurrence of non-motor symptoms in Parkinson’s disease ranging from early to advanced disease, Mov Disord, 2004;19(Suppl. 9):S406.
11. Rahman S, Griffin HJ, Quinn NP, et al., Quality of life in Parkinson's disease: the relative importance of the symptoms, Mov Disord, 2008;23:1428–34.
12. Barone P, Antonini A, Colosimo C, et al., The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease, Mov Disord, 2009;24:1641–9.
13. Chaudhuri KR, Martinez-Martin P, Brown RG, et al., The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study, Mov Disord, 2007;22:1901–11.
14. Chaudhuri KR, Yates L, Martinez-Martin P, The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential, Curr Neurol Neurosci Rep, 2005;5:275–83.
15. Martinez-Martin P, Rodriguez-Blazquez C, Abe K, et al., International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease, Neurology, 2009;73:1584–91.
16. Hely MA, Reid WG, Adena MA, et al., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years, Mov Disord, 2008;23:837–44.
17. Weintraub D, Moberg PJ, Duda JE, et al., Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease, J Am Geriatr Soc, 2004;52:784–8. 18. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al., The
nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire, Mov Disord, 2010;25:697–701.
19. Shulman LM, Taback RL, Rabinstein AA, et al., Non-recognition of depression and other non-motor symptoms in Parkinson's disease, Parkinsonism Relat Disord, 2002;8:193–7.
20. Martinez-Martin P, Deuschl G, Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease, Mov Disord, 2007;22:757–65.
21. Zesiewicz TA, Sullivan KL, Arnulf I, et al., Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 2010;74:924–31.
22. Chaudhuri KR, Schapira AH, Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment, Lancet Neurol, 2009;8:464–74.
23. Trenkwalder C, Kies B, Rudzinska M, et al., Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo- controlled study (RECOVER) Mov Disord, 2011;26(1):90–9.
24. Naidu Y, Tluk S, Martin A, et al., Initiation of apomorphine infusion in advanced Parkinson's disease and effect on non motor symptoms compared to non-invasive strategies, Mov Disord, 2009;24(Suppl. 1):S360.
25. Honig H, Antonini A, Martinez-Martin P, et al., Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life, Mov Disord, 2009;24:1468–74.
EUROPEAN NEUROLOGICAL REVIEW SUPPLEMENT
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39